Trial Profile
Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms ACTIF
- 03 Apr 2022 Status changed from recruiting to completed.
- 01 Apr 2022 This trial has been completed in France (End Date: 26 Oct 2010), according to European Clinical Trials Database record.
- 26 Mar 2022 This trial has been completed in Belgium (End Date: 26 Oct 2010), according to European Clinical Trials Database record.